Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opdivo Overtakes Keytruda, Fueled By Lung Cancer Use

Executive Summary

In the second quarter, Bristol notes rapid uptake for PD-1 inhibitor Opdivo in lung cancer, while Merck touts dominant position in U.S. melanoma market for its competing Keytruda.

Advertisement

Related Content

Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel